TTyris Tx
Tyris Tx (legally Tyris Therapeutics S.L.) is a preclinical-stage biotech developing next-generation non-viral, DNA-based gene therapies. Its platform pairs a proprietary synthetic linear closed DNA format (oDNA™) with novel non-viral vectors that have no cargo-size limit and allow re-dosing, with a pipeline focused on dermatological, renal, haematological and pulmonary indications. It was created in 2020 as a company-builder venture wholly owned by Columbus Venture Partners, is headquartered in the Paterna technology park near Valencia, and signed a strategic gene-therapy partnership with Almirall in January 2021.
SectorsBiotech, Gene Therapy, Pharmaceuticals, Life Sciences, Healthtech & Bio
Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers
Founders
D
Damià Tormo
Founder (Managing Partner, Columbus Venture Partners; former CEO of Tyris)
Also at Columbus Venture Partners
+1
Global models 5
TTessera Therapeutics
United States · www.tesseratx.com ↗
Preclinical platform biotech building non-viral genetic medicines that deliver DNA and RNA cargo without viral vectors, allowing re-dosing.
$580MComparable
RReCode Therapeutics
United States · recodetx.com ↗
Develops non-viral genetic medicines on a lipid-nanoparticle delivery platform with a pulmonary-first pipeline, the same repeat-dosable non-viral approach.
$260MComparable
G
Generation Bio
United States · generationbio.com ↗
Raised venture money for closed-ended synthetic DNA (ceDNA) gene therapy carried by non-viral vectors, with no cargo-size limit and re-dosing, the closest match to Tyris's oDNA approach.
$220MComparable
S
SalioGen Therapeutics
United States · www.saliogen.com ↗
Preclinical biotech developing non-viral DNA gene-insertion therapies meant to deliver large genes without viral vectors.
$135MComparable
TTouchlight
United Kingdom · www.touchlight.com ↗
Builds a synthetic linear closed-ended DNA platform (doggybone DNA) for non-viral genetic medicines, the technology closest to Tyris's oDNA format.
$125MComparable
In the same niche 67 others
See all in the Start-ups Map →
Notes: Most funded first
Investors 1
Open as list →
Funding rounds
No announced rounds on record.
News 1
Open as list →| Published | Article |
|---|---|
| 2023-10-02 |
AVI funding, obtained by Tyris Therapeutics, enables to validate the synthetic DNA to develop Gene Therapies ↗
Tyris Tx (press release)
2023-10-02 |